HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Ulrike Bacher Selected Research

S63845

7/2021Rationale for a Combination Therapy with the STAT5 Inhibitor AC-4-130 and the MCL1 Inhibitor S63845 in the Treatment of FLT3-Mutated or TET2-Mutated Acute Myeloid Leukemia.
2/2021BMI1-Inhibitor PTC596 in Combination with MCL1 Inhibitor S63845 or MEK Inhibitor Trametinib in the Treatment of Acute Leukemia.
11/2019Rationale for a Combination Therapy Consisting of MCL1- and MEK-Inhibitors in Acute Myeloid Leukemia.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Ulrike Bacher Research Topics

Disease

38Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
02/2022 - 04/2005
24Neoplasms (Cancer)
01/2022 - 01/2009
18Myelodysplastic Syndromes (Myelodysplastic Syndrome)
03/2022 - 01/2010
12Residual Neoplasm
01/2022 - 01/2008
12Leukemia
10/2021 - 05/2007
12BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia)
12/2020 - 04/2005
11Multiple Myeloma
01/2019 - 07/2009
7Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
11/2022 - 04/2005
6Graft vs Host Disease (Graft-Versus-Host Disease)
01/2022 - 05/2009
6Lymphoma (Lymphomas)
02/2021 - 10/2015
6Primary Myelofibrosis (Myelosclerosis)
12/2020 - 02/2009
6Hematologic Neoplasms (Hematological Malignancy)
11/2019 - 08/2008
5Chromosome Aberrations (Chromosome Abnormalities)
01/2021 - 10/2009
4Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse)
06/2022 - 11/2012
4B-Cell Lymphoma (Lymphoma, B Cell)
05/2022 - 01/2010
4Pathologic Complete Response
01/2022 - 01/2013
3Mantle-Cell Lymphoma (Lymphoma, Mantle Cell)
04/2022 - 12/2013
3Fever (Fevers)
02/2021 - 01/2017
3B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
01/2019 - 05/2011
3Bronchiolitis Obliterans Syndrome
10/2015 - 08/2008
2Chronic Myelomonocytic Leukemia (Leukemia, Chronic Myelomonocytic)
04/2022 - 01/2011
2Blast Crisis (Blast Phase)
10/2020 - 03/2010
2Thrombocytosis (Thrombocythemia)
04/2019 - 05/2013
2Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular)
01/2018 - 12/2015
2Hodgkin Disease (Hodgkin's Disease)
10/2016 - 01/2011
2Refractory Anemia
05/2013 - 06/2007
2Acute Promyelocytic Leukemia
12/2011 - 05/2007
2Aplastic Anemia (Anemia, Hypoplastic)
01/2011 - 05/2010
1T-Cell Prolymphocytic Leukemia (Leukemia, T Cell, Chronic)
01/2022
1Transthyretin-Related Hereditary Amyloidosis
10/2021
1Amyloidosis
10/2021
1COVID-19
06/2021
1Pulmonary Edema
02/2021
1Exanthema (Rash)
02/2021
1Diarrhea
02/2021
1Germ Cell and Embryonal Neoplasms (Germ Cell Tumor)
02/2021
1Burkitt Lymphoma (Burkitt's Lymphoma)
01/2021
1Neutropenia
12/2020
1Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
11/2020
1monosomy Chromosome 7
01/2020
1Cytokine Release Syndrome
01/2020
1Myeloid Leukemia (Leukemia, Myelocytic)
11/2019

Drug/Important Bio-Agent (IBA)

6Tyrosine Kinase InhibitorsIBA
01/2020 - 01/2009
4Chimeric Antigen ReceptorsIBA
05/2022 - 01/2020
4Busulfan (Busulfex)FDA Link
02/2022 - 08/2008
4Melphalan (Alkeran)FDA LinkGeneric
02/2022 - 01/2017
4Biomarkers (Surrogate Marker)IBA
04/2019 - 06/2011
4Biological ProductsIBA
08/2014 - 01/2010
4Imatinib Mesylate (Gleevec)FDA Link
01/2011 - 03/2010
3fludarabineIBA
11/2021 - 01/2013
3S63845IBA
07/2021 - 11/2019
3Antilymphocyte Serum (Anti-Thymocyte Globulin)IBA
01/2020 - 08/2008
3Rituximab (Mabthera)FDA Link
01/2020 - 01/2010
3AntigensIBA
05/2013 - 01/2011
3Protein-Tyrosine Kinases (Tyrosine Kinase)IBA
10/2012 - 01/2008
2Cyclophosphamide (Cytoxan)FDA LinkGeneric
11/2022 - 02/2022
2Pharmaceutical PreparationsIBA
01/2022 - 01/2017
2Mitogen-Activated Protein Kinase Kinases (MEKs)IBA
02/2021 - 11/2019
2trametinibIBA
02/2021 - 11/2019
2Immunoglobulin G (IgG)IBA
11/2020 - 10/2015
2Core Binding Factors (Core-Binding Factor)IBA
01/2020 - 07/2010
2Proteins (Proteins, Gene)FDA Link
11/2019 - 10/2012
2Lenalidomide (CC 5013)FDA Link
01/2019 - 06/2017
2EpitopesIBA
01/2016 - 05/2011
2Phosphotransferases (Kinase)IBA
10/2010 - 06/2010
1Antineoplastic Agents (Antineoplastics)IBA
01/2022
1Prealbumin (Transthyretin)IBA
10/2021
1fms-Like Tyrosine Kinase 3IBA
07/2021
1PTC596IBA
02/2021
1Adrenal Cortex Hormones (Corticosteroids)IBA
02/2021
1idelalisibIBA
01/2021
1Darbepoetin alfa (Aranesp)FDA Link
12/2020
1isocitric acid (isocitrate)IBA
10/2020
1Vitamin DFDA LinkGeneric
10/2020
1AcidsIBA
10/2020
1Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA
10/2020
1Acute-Phase Proteins (Acute-Phase Protein)IBA
02/2020
1Interleukin-6 (Interleukin 6)IBA
01/2020
1Alemtuzumab (Campath)FDA Link
01/2020
1Dihydrotachysterol (AT 10)IBA
01/2020
1InterleukinsIBA
01/2020
1MicroRNAs (MicroRNA)IBA
01/2020
1Therapeutic UsesIBA
01/2020
1Bendamustine HydrochlorideFDA Link
12/2019
1siremadlinIBA
11/2019
1plerixaforFDA Link
01/2019

Therapy/Procedure

44Stem Cell Transplantation
06/2022 - 08/2008
24Therapeutics
05/2022 - 05/2007
23Cell Transplantation
11/2022 - 01/2012
16Transplantation
04/2022 - 09/2010
15Hematopoietic Stem Cell Transplantation
01/2021 - 12/2010
10Drug Therapy (Chemotherapy)
06/2022 - 12/2011
8Homologous Transplantation
11/2021 - 09/2010
4Hematopoietic Stem Cell Mobilization
01/2020 - 01/2018
4Induction Chemotherapy
01/2020 - 07/2006
3Autologous Transplantation
01/2020 - 01/2018
1Donor Selection
03/2022
1MDC protocol
01/2022
1Treatment Delay
10/2021
1Precision Medicine
06/2021